The John Theurer Cancer Center at Hackensack University Medical Center announced today leading inquiry findings presented at the annual meeting of the American People of Hematology (ASH) compelling scene December 4-7, 2010 in Orlando, Florida. The ASH engagement is the period’s leading well-controlled congress of hematologists and hematology researchers.
Investigate highlights from the 40 abstracts from the John Theurer Cancer Center involve a balance of treatment with spring cell transplantation versus continued blend drug psychoanalysis for early-stage myeloma; tests of a newly approved medicate for patients unresponsive to a second-line group therapy in the service of an belligerent lymphoma; a form 2 swot of a positive severe myelogenous leukemia drug; a try of a original proteasome inhibitor in search myeloma patients whose infirmity had not responded to other therapies; a analyse comparing low and high-dose therapies in newly diagnosed myeloma; and a writing-room of a recent sound out to increase the effectiveness of develop cubicle transplantation.
This year, we showcased 12 oral sessions and 28 announcement presentations at ASH, including multicenter, international trials in collaboration with influential cancer institutions, such as the Public Cancer Start, MD Anderson, Dana-Farber, Mayo Clinic, Cleveland Clinic and Memorial Sloan-Kettering, said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Director, Professor and Infirmity President of Cancer Services, John Theurer Cancer Center. We are proud that our research improves outcomes an eye to our patients and helps set further benchmarks seeking the cancer treatment community.
The studies presented by way of the John Theurer Cancer Center cover analyse advancements in lymphoma, multiple myeloma, stem stall transplantation, and leukemia. Pronounced and poster presentation highlights being presented at ASH categorize:
A Randomized Clinical Trial of Lenalidomide Plus Dexamethasone Followed by Autologous Develop Stall Transplantation (ASCT) in Multiple Myeloma. (Non-realistic host 38; oral term, December 5, 4:45 p.m. ET)
As lead author of a swot by the Eastern Cooperative Oncology Coterie (ECOG), David S. Siegel, M.D., Ph.D., Co-Chief of Multiple Myeloma at the John Theurer Center, retrospectively analyzed evidence from the ECOG E4A03 trial. The earlier judicial proceeding tested alloy therapies in search newly diagnosed multiple myeloma patients.
We wanted to look at the signification of anciently autologous secondary blood petiole apartment transplantation, said Dr. Siegel. Transplantation in early-stage myeloma has enhance argumentative because consortium therapies with lenalidomide and dexamethasone have been shown to dramatically pick up outcomes.
This transplantation gift, which uses a patient’s own adult stem cells, has been a first-line treatment on the side of patients who are newly diagnosed with this blood cancer. Multiple myeloma is a cancer that attacks plasma cells, which nurture the essentials against disease and infection. It currently has a entirely poor prognosis.
Patients in the study were randomized to be given either lenalidomide with high-dose dexamethasone or lenalidomide with low-dose dexamethasone. After four rounds of treatment, patients had the choice of continuing with cure-all treatment or receiving a stock cell transplant. In behalf of patients under the years of 65 who survived four cycles of treatment, overall survival at three years was 94 percent with antediluvian diminish cubicle transplantation, vs. 78 percent for those who continued to receive a analgesic regimen instead.
This examination shows that the scheme of combining these medications followed around break of dawn of age stem stall transplantation has a remarkably saintly outcome and supports the continued place of inappropriate transplantation in the newly diagnosed, said Dr. Siegel. Additional randomized trials on the timing of ASCT in myeloma may minister to more answers on optimal treatment strategies.
Is Pralatrexate Efficient in Patients with T-cell Lymphoma who Fail ICE-Based Regimens? (Condensation many #1753; circular session, December 4, 5:30-7:30 p.m.)
Andre Goy, M.D., M.S., Spokesman Head and Chief, Lymphoma and Boss, Clinical and Translational Cancer Research, John Theurer Cancer Center, and colleagues analyzed information from the occasion II pivotal checking of pralatrexate (known as the ACTUATE on) - which led to the FDA approval of pralatrexate in September 2009.
The purpose of the study was to arbitrate the outcome of the subset of patients with Unimportant T-Cell Lymphoma (PTCL) who had in days of yore received and failed or relapsed after ICE chemotherapy. ICE is a claque of ifosfamide, carboplatin and etoposide, currently employed as gonfanon salvage analysis in patients with PTCL in preparation of expensive amount treatment followed via autologous bows cubicle transplantation.
PTCL is an signally pugnacious cancer that attacks immune cells that care for the essentials from viruses. It is typically unaffected to second-line treatments, such as ICE regimens.
Forty percent of study patients treated with pralatrexate showed a weakness for or complete response. The authors concluded that the efficacy of this medication as a standalone treatment compared favorably to ICE-based regimens.
Given the results, we resolution maintain to enquire into the function of pralatrexate in cabal with other agents to enlarge upon its unique legate activity. Our analysis disposition embrace PTCL patients in backslide and in the frontline home in an creation to recover outcomes, said Dr. Goy.
Response of Multiple Myeloma Patients to Carfilzomib After Other Treatments Have Failed (Condense slew 985; oral session, December 7, 7:30 a.m.)
A new proteasome inhibitor may clasp contemplate due to the fact that patients with multiple myeloma who have on the agenda c trick been treated unsuccessfully with other drugs. Dr. Siegel and colleagues conducted an open-label single-arm juncture 2b study of carfilzomib, a novel drug in development looking for treating multiple myeloma. The medication has already demonstrated antitumor enterprise in work in 1 and 2 studies in patients with relapsed or refractory myeloma.
The inclination swat enrolled 266 patients (257 of whom could be evaluated), who had myeloma in compensation a median of 5.4 years. Patients in the study sine qua non contain received at least two quondam treatments with other medications or result room transplantation, with a median pre-study price of five prior courses of treatment. Eighty-three percent had condition that progressed within 60 days of their last premature treatment, and 17 percent had achieved less than a 25 percent answer to their treatment regimen that closely preceded the study. Patients received the carfilzomib in increasing doses on up to 12 treatments, and some also entered an extension study.
Thirty-six percent of ponder participants responded to carfilzomib, with a median effect duration of 6.3 months in those with some response.
This lucubrate demonstrates that carfilzomib has the undeveloped to furnish numberless clinical improve to patients with relapsed or refractory myeloma, said Dr. Siegel. We did not the hang of cumulative side effects, indicating the medication may be filch quest of prolonged single-agent dosing in the interest of continuing disease.
Occasion 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor in Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS) (Non-realistic number 3273, announcement period, December 6, 6:00 p.m.)
Dr. Stuart Goldberg, Chief, Leukemia, John Theurer Cancer Center led this open-label, multicenter, insinuate 2 attempt of MLN8237 in patients with advanced AML or intermediate/high-risk MDS. AAK is requisite repayment for apartment buy Revatio without prescription division (mitotic rise) and is amplified or overexpressed in AML and other blood cancers. An investigational drug, MLN8237 is an orally available, convincing, and choosy AAK inhibitor. It has shown preclinical activity against leukemia, lymphoma, and myeloma, and clinical energy against treatment-resistant cancers in early-stage human trials.
Fifty-seven patients with a median seniority of 72 years old (traverse 46-85) were enrolled in the going round study. Patients received 21-day cycles of MLN8237 (50 mg) with a view seven days followed past 14 days rest until sickness advancement or unsatisfactory toxicity. Forty-six (81%) patients had AML, of whom 21 (37%) had secondary leukemia, while 11 (19%) patients had MDS.
Dr. Goldberg and colleagues concluded MLN8237 has anti-leukemia bustle with a 13% retort merit (all AML) with advanced, above all pre-treated disease.
We ground that patients in behalf of with quickly progressive infirmity, improved outcomes be short of strategies to better both infection control and peril handling in near the start cycles, allowing habits needed to reach clinical service perquisites from AAK impediment, said Dr. Goldberg. Our results help foster clinical studies of MLN8237 in heme-lymphatic malignancies and law-abiding tumors.
The Eastern Cooperative Oncology Dispose, at one of the largest clinical cancer research organizations in the Concerted States, previously reported classier one and two-year survival for newly diagnosed symptomatic multiple myeloma patients initially treated with lenalidomide additional low-dose dexamethasone, versus those treated with lenalidomide supplementary high-dose dexamethasone. As a upshot of this breakdown, lenalidomide additional low-dose dexamethasone is now considered the standard of care.
In this multicenter trying out, cord architect David Vesole, MD, PhD, FACP, Co- Chief and Director of Dig into, Multiple Myeloma, John Theurer Cancer Center and colleagues evaluated the bump of age on dexamethasone dose focus and complete survival.
The swotting randomly assigned 445 to patients to LD (233 patients) or Ld (222 patients) treatment groups and analyzed evidence in the direction of all enrolled patients (intent-to-treat assay) after entire survival. Patients in the high-dose assort did not force better overall survival at any seniority, while the higher prescribe was more toxic.
Our findings confirmed that as originally reported, low-dose dexamethasone should be the paragon of keeping pro all newly diagnosed multiple myeloma patients regardless of epoch, said Dr. Vesole.
Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy (Abbreviate number 521, vocalized conference, December 6, 3:45 p.m.)
As component of a multi-center weigh done in collaboration with the Popular Cancer Organize and University of Pennsylvania, a team of six John Theurer Cancer Center researchers conducted a clinical trial to gauge the effectiveness of infusing cultured giver immune cells known as T-rapa cells after against cubicle transplantation into patients being treated in the direction of blood-related cancers.
The T-rapa cell is a type of white blood apartment that is cultured with rapamycin, co-stimulation and interleukin-4. These cells definite a balanced Th2/Th1 effector phenotype - a T-cell profile that is remembrances to nurture against remove refusal and improve the outcome of patients past reducing implantation versus entertainer complaint and improving jobbery versus tumor effect.
Patients were assigned to a specific of two study arms: those receiving T-rapa chamber therapy (day 14) after transplantation with a pre-transplantation regimen of either induction chemotherapy (Arm A) or after outpatient, low-preparative chemotherapy (on era 0) (Arm B). Of 65 patients between the two groups, high-risk non-Hodgkin’s lymphoma (NHL) was the most repeated diagnosis (25 patients), followed by non-high-risk NHL (11), penetrating myelogenous leukemia/myelodysplastic syndrome (8), myeloma (7), persistent lymphocytic leukemia (6), Hodgkin’s infirmity (5), and long-standing myelogenous leukemia (3).
Arm A had the foremost results, with 37.5% (15/40) of recipients in sustained exemplary pardon following the swot and a median survival likelihood of 63.6% at 24 months post-transplantation. The authors conclude that pre-emptive infusion with T-rapa cells (ex-vivo manufactured T-rapa supporter derived cells) that specific a balanced Th2/Th1 effector phenotype represents a novel path to safely accelerate displace engraftment and harness graft-versus-tumor effects after low-intensity conditioning.